Trends in use of cardioprotective medication in peripheral artery disease: A nationwide study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Trends in use of cardioprotective medication in peripheral artery disease : A nationwide study. / Kamil, Sadaf; Sehested, Thomas S.G.; Houlind, Kim; Lassen, Jens F.; Gislason, Gunnar H.; Dominguez, Helena.
I: Journal of the American Heart Association, Bind 10, Nr. 15, e020333, 2021.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Trends in use of cardioprotective medication in peripheral artery disease
T2 - A nationwide study
AU - Kamil, Sadaf
AU - Sehested, Thomas S.G.
AU - Houlind, Kim
AU - Lassen, Jens F.
AU - Gislason, Gunnar H.
AU - Dominguez, Helena
N1 - Publisher Copyright: © 2021 The Authors. Published on behalf of the American Heart Association.
PY - 2021
Y1 - 2021
N2 - BACKGROUND: Guideline-based cardioprotective medical therapy is intended to reduce the burden of adverse cardiovascular and limb outcomes in patients with peripheral artery disease (PAD). However, contemporary data describing trends in use of medication remains limited. The present study, therefore, aims to investigate changes in use of cardioprotective medication in PAD. METHODS AND RESULTS: By using Danish national healthcare registries, we identified all patients with first-time diagnosis of PAD (1997–2016) and classified them into two groups: (1) PAD+ that includes all patients with PAD with a history of cardiovascular disease, ie, myocardial infarction, atrial fibrillation, and stroke (n=162 627); and (2) PAD (n=87 935) that comprise patients without a history of cardiovascular disease. We determined the use of medication in the first 12 months after the incident diagnosis of PAD and estimated age standardized 1-year mortality rates. Our results showed increase in use of cardioprotective medication throughout the study period in both groups. However, PAD+ had a higher use of medication (acetylsalicylic acid, 3.5%–48.4%; Clopidogrel, 0%–17.6%; vitamin K antagonists, 0.9%–7.8%; new oral anticoagulants, 0.0%– 10.1%; Statins, 1.9%–58.1%; angiotensin-converting enzyme inhibitors, 1.2%–20.6%), compared with PAD (acetylsalicylic acid, 2.9%–54.4%; Clopidogrel, 0%–11.9%; vitamin K antagonists, 0.9%–2.4%; new oral anticoagulants, 0.0%–3.4%; Statins, 1.5%–56.9%; angiotensin-converting enzyme, 0.9%–17.2%), respectively. Furthermore, 1-year mortality rates in PAD declined with increased use of medications during study. CONCLUSIONS: In this nationwide study, use of cardioprotective medication increased considerably with time, but compared to patients with other atherosclerotic diseases, there remains an underuse of guideline-based medical therapy in patients with PAD.
AB - BACKGROUND: Guideline-based cardioprotective medical therapy is intended to reduce the burden of adverse cardiovascular and limb outcomes in patients with peripheral artery disease (PAD). However, contemporary data describing trends in use of medication remains limited. The present study, therefore, aims to investigate changes in use of cardioprotective medication in PAD. METHODS AND RESULTS: By using Danish national healthcare registries, we identified all patients with first-time diagnosis of PAD (1997–2016) and classified them into two groups: (1) PAD+ that includes all patients with PAD with a history of cardiovascular disease, ie, myocardial infarction, atrial fibrillation, and stroke (n=162 627); and (2) PAD (n=87 935) that comprise patients without a history of cardiovascular disease. We determined the use of medication in the first 12 months after the incident diagnosis of PAD and estimated age standardized 1-year mortality rates. Our results showed increase in use of cardioprotective medication throughout the study period in both groups. However, PAD+ had a higher use of medication (acetylsalicylic acid, 3.5%–48.4%; Clopidogrel, 0%–17.6%; vitamin K antagonists, 0.9%–7.8%; new oral anticoagulants, 0.0%– 10.1%; Statins, 1.9%–58.1%; angiotensin-converting enzyme inhibitors, 1.2%–20.6%), compared with PAD (acetylsalicylic acid, 2.9%–54.4%; Clopidogrel, 0%–11.9%; vitamin K antagonists, 0.9%–2.4%; new oral anticoagulants, 0.0%–3.4%; Statins, 1.5%–56.9%; angiotensin-converting enzyme, 0.9%–17.2%), respectively. Furthermore, 1-year mortality rates in PAD declined with increased use of medications during study. CONCLUSIONS: In this nationwide study, use of cardioprotective medication increased considerably with time, but compared to patients with other atherosclerotic diseases, there remains an underuse of guideline-based medical therapy in patients with PAD.
KW - Atrial fibrillation
KW - Myocardial infarction
KW - Peripheral artery disease
KW - Stroke
KW - Temporal trends
U2 - 10.1161/JAHA.120.020333
DO - 10.1161/JAHA.120.020333
M3 - Journal article
C2 - 34315233
AN - SCOPUS:85112373088
VL - 10
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
SN - 2047-9980
IS - 15
M1 - e020333
ER -
ID: 302043455